CELL INTELLIGENCE · 肿瘤细胞治疗研究

未成熟脐带血 NK 亚群的清除可逆转胞啃作用驱动的 CAR NK 功能障碍

Depletion of an immature cord blood NK subset reverses trogocytosis-driven CAR NK dysfunction.

IL1RAP CAR 修饰的 TGFβ1 印记 NK 细胞联合 IL-15 激动剂与抗 GD2 抗体克服尤因肉瘤肿瘤微环境耐药

Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 ag

我们的临床前数据表明，利用靶向肿瘤的 TGFβ1 印记 IL1RAP-CAR-NK 细胞，联合 IL-15 激动剂和抗 GD2 抗体所进行的组合性先天免疫治疗，是一种有前景的针对转移性/复发性/难治性 ES 的新型治疗策略。

推进 CAR-NK 细胞疗法在实体瘤中的应用：当前格局与未来方向

Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions.

探索 CAR-T 之外的 CAR 细胞疗法用于髓系恶性肿瘤

Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.

重编程抗肿瘤免疫：NK 细胞穿越免疫抑制性肿瘤微环境的策略

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.

B 细胞淋巴瘤中的 CAR-NK 细胞：迈向可及且可扩展细胞治疗的新前沿

CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy.

TAK-007 在复发/难治性 B 细胞非霍奇金淋巴瘤成人患者中的安全性和疗效：一项 2 期开放标签多中心研究

A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

障碍与蓝图：胃肠道肿瘤 CAR-T 细胞治疗的下一代工程策略

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.

儿童实体瘤的生物工程细胞疗法：未满足需求与测量整合方法

Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.

开发基于溶瘤病毒递送 CD19 和 EGFRvIII 抗原与双特异性 CAR 的胶质母细胞瘤多模式治疗

Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.